Related Experiment Video

Updated: Jun 15, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Bitter melon: antagonist to cancer

Pratibha Nerurkar1, Ratna B Ray

  • 1Laboratory of Metabolic Disorders and Alternative Medicine, University of Hawaii, Honolulu, Hawaii, USA.

Pharmaceutical Research
|March 4, 2010
PubMed

Insights

Bitter melon (Momordica charantia), a traditional Ayurvedic remedy, shows promise in cancer prevention and treatment. Its compounds induce cancer cell death and cycle arrest with minimal side effects, offering a cost-effective dietary approach.

Area of Science:

  • Oncology
  • Nutritional Science
  • Traditional Medicine

Background:

  • Global cancer incidence is rising despite advances in therapies.
  • Dietary interventions are explored for cancer prevention by inhibiting neoplastic events.
  • Bitter melon (Momordica charantia) is an Ayurvedic remedy with a history of use for diabetes and potential anti-cancer properties.

Purpose of the Study:

  • To review recent advancements in the chemopreventive and anti-cancer efficacy of bitter melon and its constituents.
  • To highlight bitter melon's potential role in cancer control through dietary intervention.

Main Methods:

  • Review of scientific literature on bitter melon's anti-cancer effects.
  • Analysis of studies investigating bitter melon's impact on cancer cell lines.
  • Examination of bitter melon's mechanism of action, including cell cycle regulation and apoptosis induction.

Main Results:

  • Bitter melon extracts demonstrate anti-tumor activity in various cancer cell lines.
  • Treatment with bitter melon products induces cell cycle arrest and apoptosis.
  • These effects occur without adversely impacting normal cell growth, indicating selectivity.
  • Bitter melon exhibits a low side-effect profile in animal and human studies.

Conclusions:

  • Bitter melon possesses significant cancer chemopreventive and anti-cancer potential.
  • Its active constituents can inhibit carcinogenesis by regulating cell homeostasis and apoptosis.
  • Bitter melon represents a safe, cost-effective, and beneficial dietary approach for cancer health.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...